Table 2.
Platelet function, activation and sensitivity to prostacyclin, and clotting function/lysis at baseline and after treatment with liraglutide
| Variable | PCOS | Controls | PCOS | Controls | Between groups difference | |
|---|---|---|---|---|---|---|
| Baseline mean (SD) | Baseline mean (SD) | 6-months-baseline | 6-months-baseline | 95% CI | P-value | |
| Platelets P-selectin expression | ||||||
| Basal activation | 0.52 (0.3) | 0.42 (0.2) | −0.12 | −0.17† | −0.14 – 0.26 | 0.41 |
| ADP 0.1 μM | 3.1 (2.9) | 2.8 (2.1) | −0.09 | −0.16 | −1.6 – 1.7 | 0.42 |
| ADP 1 μM | 40.2 (14.5) | 44.0 (13.5) | 0.2 | −1.1 | −4.8 – 7.3 | 0.74 |
| ADP 10 μM | 61.6 (13.6) | 66.9 (13.1) | −0.1 | 2.9 | −8.7 – 2.8 | 0.30 |
| % inhibition by PGI2: | ||||||
| 1 nM | 17.5 (14.1) | 17.8 (10.9) | 3.4 | 6.0 | −9.8 – 4.6 | 0.80 |
| 10 nM | 65.5 (11.7) | 66.5 (9.6) | 3.5 | 3.0 | −7.1 – 8.1 | 0.67 |
| 100 nM | 79.3 (6.5) | 77.4 (7.1) | 1.7 | 2.5 | −5.6 – 4.0 | 0.74 |
| Platelets fibrinogen binding | ||||||
| Basal activation | 0.97 (0.4) | 0.83 (0.3) | −0.04 | 0.09 | −0.4 – 0.13 | 0.31 |
| ADP 0.1 μM | 9.7 (10.0) | 7.7 (7.1) | 1.6 | −2.6 | −0.06 – 8.4 | 0.13 |
| ADP 1 μM | 55.9 (18.4) | 55.8 (19.0) | 0.6 | −4.6 | −3.4 – 13.8 | 0.30 |
| ADP 10 μM | 73.7 (14.6) | 76.2 (11.7) | 1.1 | −4.0 | −0.95 – 11.2 | 0.10 |
| % inhibition by PGI2: | ||||||
| 1 nM | 41.5 (23.2) | 46.7 (17.6) | 5.6 | 3.6 | −13.7 – 17.6 | 0.90 |
| 10 nM | 95.8 (2.3) | 96.8 (2.1) | 0.7 | 0.1 | −0.9 – 2.5 | 0.28 |
| 100 nM | 97.8 (1.1) | 98.0 (1.4) | 0.5 | 0.2 | −0.4 – 1.7 | 0.21 |
| Clot function/lysis | ||||||
| Lag phase (sec) | 379 (64) | 380 (45) | 96† | 139† | −99 – 12.8 | 0.13 |
| Lysis area (au) | 586 (292) | 538 (177) | −108† | −100† | −139 – 124 | 0.59 |
| Maximum absorbance (au) | 0.39 (0.1) | 0.41 (0.1) | −0.01 | −0.03 | −0.03 – 0.06 | 0.49 |
| Clot formation time (sec) | 609 (190) | 583 (144) | 69 | 40 | −83 – 140 | 0.61 |
| Lysis time (sec) | 766 (204) | 743 (117) | 7.1 | 20.9 | −136 – 108 | 0.82 |
Platelet surface expression (% of positive cells) of P-selectin and fibrinogen binding were measured in unstimulated samples (basal activation) and after stimulation with ADP 0.1-10 μM for 20 minutes before fixing with 0.2% paraformaldehyde. For platelet sensitivity to PGI2, samples were pre incubated with PGI2 1, 10, and 100 nM for 90 seconds before; stimulation with ADP 10 μM and fixing at 20 minutes for P-selectin expression; or stimulation with ADP 1 μM and fixing at 5 minutes for fibrinogen binding. Data are presented as mean (standard deviation (SD)). ADP, adenosine-5’-diphosphate; PGI2, prostacyclin; sec, seconds; au, arbitrary unit. Comparisons at baseline were not statistically significant (all P values were >0.05). †Significant within group change, 6-month vs. baseline, P < 0.05.